4 to 8, 2025, looked at medical records from people on GLP-1s who received PET-CT scans
[DOI] [PMC free article] [PubMed] [Google Scholar] 54.Cermolacce M., Belzeaux R., Adida M., Azorin J.-M
Early Discoveries, With More to Come So far, GLP-1s, first approved 20 years ago for type 2 diabetes and later obesity, have shown potential in treating a surprisingly wide range of conditions, such as heart disease, Parkinsons, Alzheimers, sleep apnea, and liver disease
Most patients with a body mass index (BMI) over 30 or a BMI over 27 with weight-related health conditions such as hypertension or diabetes may be considered for GLP-1 treatment after a medical evaluation with Dr
Monitoring lipid levels helps assess overall cardiovascular health, particularly important given that many patients with type 2 diabetes have concurrent dyslipidemia